A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Adaptimmune Limited
Start Date
February 1, 2016
End Date
January 31, 2023
Administered By
Duke Cancer Institute
Awarded By
Adaptimmune Limited
Start Date
February 1, 2016
End Date
January 31, 2023